Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Quipt Home Medical Corp T.QIPT

Alternate Symbol(s):  QIPT

Quipt Home Medical Corp. is a home medical equipment provider. The Company specializes in improving the home management of chronic illness through the application of telehealth systems and automated distribution. It provides in-home monitoring and disease management services, including end-to-end respiratory solutions for patients in the United States. It offers nebulizers, oxygen concentrators, continuous positive airway pressure (CPAP) and Bilevel Positive Airway Pressure (BiPAP) units; traditional and non-traditional medical respiratory equipment and services, and non-invasive ventilation equipment, supplies, and services. The Company's product offerings include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. Its products and services consist of sleep apnea and pap treatment, home ventilation, daily and ambulatory aides, and respiratory equipment rental.


TSX:QIPT - Post by User

Bullboard Posts
Post by Trademark11on Aug 22, 2018 9:16am
225 Views
Post# 28498009

EBITDA Guidance from Q2 Conference call

EBITDA Guidance from Q2 Conference callListening to the May 2018 conference call, Doug Cooper asked what the company's expectation for EBITDA margins would be going forwards.  Listen to the recording of that conversation at the following link after clicking on the May 2018 conference call and forwarding to the 21 minute mark.

Long story short, the company guided towards a 2018 exit EBITDA margin of 18-22%. 
It will be interesting to see what the margin is on Tuesday.... it was 12% in Q2.  If we are looking at sequential improvement, then it would make sense for the EBITDA margin to come in between 14%-16%.  That would be an outstanding improvement.

https://www.protechhomemedical.com/conference_calls
Bullboard Posts